Skip to main content

Insulet Corporation (PODD)

NASDAQ: PODD · IEX Real-Time Price · USD
303.35 4.66 (1.56%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap20.82B
Revenue (ttm)995.60M
Net Income (ttm)-30.50M
Shares Out66.70M
EPS (ttm)-0.47
PE Ration/a
Forward PE192.31
Dividendn/a
Ex-Dividend Daten/a
Volume161,596
Open299.54
Previous Close298.69
Day's Range298.29 - 303.59
52-Week Range214.93 - 309.99
Beta0.68
AnalystsBuy
Price Target291.88 (-3.8%)
Est. Earnings DateNov 4, 2021

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is...

IndustryHealth Care Equipment & Supplies
IPO DateMay 15, 2007
CEOShacey Petrovic
Employees1,900
Stock ExchangeNASDAQ
Ticker SymbolPODD
Full Company Profile

Financial Performance

In 2020, Insulet's revenue was $904.40 million, an increase of 22.51% compared to the previous year's $738.20 million. Earnings were $6.80 million, a decrease of -41.38%.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for Insulet stock is "Buy." The 12-month stock price forecast is 291.88, which is a decrease of -3.78% from the latest price.

Price Target
$291.88
(-3.78% downside)
Analyst Consensus: Buy

News

Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

1 day ago - Zacks Investment Research

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced tha...

3 days ago - Business Wire

Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use

Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System.  Omnipod 5 is a tubeless, wearable system that continuously a...

3 weeks ago - Benzinga

Insulet's Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented posit...

3 weeks ago - Business Wire

Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pla...

3 weeks ago - Business Wire

Here's Why You Should Retain Insulet (PODD) Stock for Now

Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).

3 weeks ago - Zacks Investment Research

5 Top Stocks for September

Our analysts give you five picks you can add to your portfolio today.

Other symbols:AMZNPUBMSHOP
1 month ago - The Motley Fool

Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.

1 month ago - Zacks Investment Research

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management wi...

1 month ago - Business Wire

Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev

Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.

2 months ago - Zacks Investment Research

FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps

The FDA has approved the use of Eli Lilly And Co's (NYSE:LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ:PODD) insulin management systems. Lyumjev, approved ...

Other symbols:LLY
2 months ago - Benzinga

Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced FDA cleara...

2 months ago - Business Wire

Insulet Introduces Omnipod DASH® System at Australasian Diabetes Congress

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented the...

2 months ago - Business Wire

Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat

Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

2 months ago - Zacks Investment Research

Insulet (PODD) Q2 Earnings Lag Estimates

Insulet (PODD) delivered earnings and revenue surprises of -16.67% and 2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced fin...

2 months ago - Business Wire

3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain

Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.

Other symbols:DXCMLULU
2 months ago - The Motley Fool

Earnings Preview: Insulet (PODD) Q2 Earnings Expected to Decline

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management wi...

2 months ago - Business Wire

Insulet to Announce Second Quarter 2021 Financial Results on August 5, 2021

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pla...

3 months ago - Business Wire

Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5

Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.

3 months ago - Zacks Investment Research

Insulet's Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifes...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pro...

3 months ago - Business Wire

Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its...

3 months ago - Business Wire

Top 5 1st-Quarter Trades of Steve Mandel's Lone Pine

Lone Pine Capital, the hedge fund founded by Steve Mandel (Trades, Portfolio) in 1997, disclosed its first-quarter portfolio earlier this week.

5 months ago - GuruFocus

Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat

Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

5 months ago - Zacks Investment Research